These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 19854938)

  • 21. Synthetic α-l-Threose Nucleic Acids Targeting BcL-2 Show Gene Silencing and in Vivo Antitumor Activity for Cancer Therapy.
    Wang F; Liu LS; Lau CH; Han Chang TJ; Tam DY; Leung HM; Tin C; Lo PK
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38510-38518. PubMed ID: 31556592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts.
    Shin M; Chan IL; Cao Y; Gruntman AM; Lee J; Sousa J; Rodríguez TC; Echeverria D; Devi G; Debacker AJ; Moazami MP; Krishnamurthy PM; Rembetsy-Brown JM; Kelly K; Yukselen O; Donnard E; Parsons TJ; Khvorova A; Sontheimer EJ; Maehr R; Garber M; Watts JK
    Nucleic Acids Res; 2022 Aug; 50(15):8418-8430. PubMed ID: 35920332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of a new biocompatible poly(N-(morpholino ethyl methacrylate)-based copolymer for the delivery of ruthenium oligonucleotides, targeting HPV16 E6 oncogene.
    Reschner A; Shim YH; Dubois P; Delvenne P; Evrard B; Marcélis L; Moucheron C; Kirsch-De Mesmaeker A; Defrancq E; Raes M; Piette J; Collard L; Piel G
    J Biomed Nanotechnol; 2013 Aug; 9(8):1432-40. PubMed ID: 23926811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticles.
    Berton M; Turelli P; Trono D; Stein CA; Allémann E; Gurny R
    Pharm Res; 2001 Aug; 18(8):1096-101. PubMed ID: 11587479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interactions of amphiphilic antisense oligonucleotides with serum proteins and their effects on in vitro silencing activity.
    Felber AE; Bayó-Puxan N; Deleavey GF; Castagner B; Damha MJ; Leroux JC
    Biomaterials; 2012 Sep; 33(25):5955-65. PubMed ID: 22656448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zorro locked nucleic acid induces sequence-specific gene silencing.
    Ge R; Heinonen JE; Svahn MG; Mohamed AJ; Lundin KE; Smith CI
    FASEB J; 2007 Jun; 21(8):1902-14. PubMed ID: 17314142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.
    Grünweller A; Wyszko E; Bieber B; Jahnel R; Erdmann VA; Kurreck J
    Nucleic Acids Res; 2003 Jun; 31(12):3185-93. PubMed ID: 12799446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel antisense therapeutics delivery systems: In vitro and in vivo studies of liposomes targeted with anti-CD20 antibody.
    Meissner JM; Toporkiewicz M; Czogalla A; Matusewicz L; Kuliczkowski K; Sikorski AF
    J Control Release; 2015 Dec; 220(Pt A):515-528. PubMed ID: 26585505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome-coated lipoplex-based carrier for antisense oligonucleotides.
    Wyrozumska P; Meissner J; Toporkiewicz M; Szarawarska M; Kuliczkowski K; Ugorski M; Walasek MA; Sikorski AF
    Cancer Biol Ther; 2015; 16(1):66-76. PubMed ID: 25482931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting murine alveolar macrophages by the intratracheal administration of locked nucleic acid containing antisense oligonucleotides.
    Uemura Y; Kobayashi K
    Drug Deliv; 2019 Dec; 26(1):803-811. PubMed ID: 31385541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SIDT2 mediates gymnosis, the uptake of naked single-stranded oligonucleotides into living cells.
    Takahashi M; Contu VR; Kabuta C; Hase K; Fujiwara Y; Wada K; Kabuta T
    RNA Biol; 2017 Nov; 14(11):1534-1543. PubMed ID: 28277980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of human telomerase activity by antisense phosphorothioate oligonucleotides encapsulated with the transfection reagent, FuGENE6, in HeLa cells.
    Tamura Y; Tao M; Miyano-Kurosaki N; Takai K; Takaku H
    Antisense Nucleic Acid Drug Dev; 2000 Apr; 10(2):87-96. PubMed ID: 10805159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient in vivo delivery of antisense oligonucleotide to choroid plexus.
    Piao W; Nishina K; Yoshida-Tanaka K; Kuwahara H; Nishina T; Sakata M; Mizusawa H; Yokota T
    J Med Dent Sci; 2013 Mar; 60(1):9-16. PubMed ID: 23917958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient nuclear delivery of antisense oligodeoxynucleotides and selective inhibition of CETP expression by apo E peptide in a human CETP-stably transfected CHO cell line.
    Liu K; Ou J; Saku K; Jimi S; Via DP; Sparrow JT; Zhang B; Pownall HJ; Smith LC; Arakawa K
    Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2207-13. PubMed ID: 10479664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.
    Braasch DA; Liu Y; Corey DR
    Nucleic Acids Res; 2002 Dec; 30(23):5160-7. PubMed ID: 12466540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity.
    Cai Y; Makarova AM; Wengel J; Howard KA
    J Gene Med; 2018 Jul; 20(7-8):e3025. PubMed ID: 29800498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
    Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
    Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.